Herbal Monograph
Kava
Piper methysticum G. Forst.
Piperaceae
Pacific Island anxiolytic with potent stress-relieving properties and importa...
Overview
Plant Description
Kava is a robust, erect, perennial shrub growing 2-5 meters (6-16 feet) tall with thick, fleshy, knotted rhizomes and lateral roots that form a large underground mass weighing up to 10 kg or more in mature plants. The stems are dichotomously branched, green, slightly fleshy, and prominently jointed with swollen nodes. Leaves are large (15-30 cm long), cordate (heart-shaped), alternate, petiolate, with 9-13 prominent veins radiating from the base, glabrous above and slightly pubescent below. The plant is dioecious, bearing tiny flowers in dense axillary spikes (spadices) 3-9 cm long, though cultivated kava rarely sets seed owing to its sterile, clonally propagated nature. The species epithet 'methysticum' derives from the Greek word for 'intoxicating,' reflecting the psychoactive properties of the root beverage. There are at least 100-200 named cultivars recognized across the Pacific islands, broadly classified into 'noble' and 'non-noble' (tudei/two-day) varieties based on their kavalactone chemotype and traditional use acceptability.
Habitat
Kava is a shade-tolerant understory plant of tropical lowland forests. It thrives in humid tropical climates with consistent rainfall (2000-3000 mm per year), temperatures between 20-35 degrees C, and well-drained, rich volcanic or alluvial soils. It does not tolerate waterlogging, frost, or prolonged drought. Kava is always found below approximately 500 meters elevation and grows best under partial shade, such as beneath coconut palms or light forest canopy.
Distribution
Native to the western Pacific islands, with the center of diversity in Vanuatu, where the greatest number of cultivars are found. Cultivated throughout Melanesia (Vanuatu, Fiji, Papua New Guinea, Solomon Islands), Polynesia (Tonga, Samoa, Hawaii, Marquesas, Tahiti), and parts of Micronesia (Pohnpei, Kosrae). Vanuatu is the likely center of origin and domestication. Major commercial production occurs in Vanuatu, Fiji, Tonga, and Samoa. Kava was introduced to northern Australia and has been trialed in tropical regions worldwide.
Parts Used
Root and rhizome (Kava rhizoma, radix)
Preferred: Traditional aqueous extraction (cold-water infusion of fresh root); standardized ethanolic or acetonic extract (commercial); dried root powder in capsules
The peeled, dried root and rhizome are the official drug. In traditional Pacific Island use, fresh root is preferred and is macerated in water. The lateral roots (waka) contain the highest kavalactone concentrations (up to 15-20%), followed by the rhizome/stump (lewena, 6-12%), and the basal stem (kasa, 3-6%). WHO and all regulatory authorities specify root and rhizome only. Aerial parts (stems and leaves) must NOT be used due to the presence of the hepatotoxic alkaloid pipermethystine. The Codex Alimentarius Kava Standard and the Kava Quality Standard Initiative both specify peeled root and rhizome of noble cultivars only.
Key Constituents
Kavalactones (kavapyrones)
Kavalactones are the primary bioactive compounds responsible for kava's anxiolytic, sedative, analgesic, and muscle relaxant effects. Six major kavalactones (kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, desmethoxyyangonin) comprise approximately 96% of the total lipid-soluble kavalactone fraction. Their chemotype ratio is expressed as a six-digit code indicating the order of abundance (e.g., 246531 for a typical noble Borogu cultivar from Vanuatu). Noble cultivar chemotypes beginning with 2 (kavain) or 4 (kavain-dominant blends) are preferred for traditional and therapeutic use. Total kavalactone content in dried root ranges from 3-20% depending on cultivar, plant part, age, and processing. Multiple mechanisms of action have been identified: GABA-A receptor modulation (not at the benzodiazepine site but via alteration of lipid membrane structure affecting receptor conformation), voltage-gated sodium and calcium channel blockade, noradrenaline and dopamine reuptake inhibition, MAO-B inhibition, and CB1 receptor binding (yangonin). This polypharmacology produces anxiolysis without the cognitive impairment characteristic of benzodiazepines.
Flavokavains (chalcones)
Flavokavains are chalcone-type compounds present in kava root at low concentrations. They have attracted significant research interest for potential anticancer properties but are also implicated in the hepatotoxicity debate. Flavokavain B in particular has demonstrated hepatotoxic potential in preclinical models. Noble cultivars contain lower flavokavain concentrations than non-noble (tudei) cultivars, which is one rationale for preferring noble varieties. The flavokavain content is substantially higher in aerial parts (leaves, stem peelings) than in the root, further supporting the restriction to root-only preparations.
Piperidine alkaloids
The piperidine alkaloids are NOT desirable therapeutic constituents. They are concentrated in aerial parts (leaves, stem peelings) that are explicitly excluded from traditional preparation. Their presence in commercial products would indicate adulteration with non-root plant material. Pipermethystine is the most toxicologically significant, with demonstrated hepatocytotoxicity in vitro. The isolation and characterization of these alkaloids by Dragull et al. (2003) was an important finding in understanding the hepatotoxicity controversy, as it provided a plausible mechanism for liver injury when non-root parts contaminate commercial preparations.
Other constituents
The non-kavalactone constituents contribute to the overall matrix of the traditional preparation. The presence of glutathione and other thiols in fresh aqueous preparations may provide endogenous hepatoprotection absent from organic solvent extracts. The high starch and fiber content of the root may moderate the rate of kavalactone absorption in traditional preparations.
Herbal Actions
Reduces anxiety
Kava is one of the most well-evidenced herbal anxiolytics. The Cochrane review by Pittler & Ernst (2003) concluded that kava extract is superior to placebo for short-term treatment of anxiety. Sarris et al. (2013) demonstrated efficacy comparable to buspirone and opipramol in an RCT for GAD. Multiple mechanisms contribute: kavalactones modulate GABA-A receptor conformation via lipid membrane interactions (distinct from benzodiazepine binding), block voltage-gated sodium and calcium channels, inhibit noradrenaline reuptake, and yangonin engages CB1 receptors. Crucially, kava produces anxiolysis WITHOUT the cognitive impairment, dependence potential, or rebound anxiety associated with benzodiazepines.
[5, 6, 7, 13]Promotes sleep and deep relaxation
Dose-dependent sedative effects are well documented. Dihydromethysticin and dihydrokavain are the most sedating kavalactones. At traditional ceremonial doses, kava produces a state of calm relaxation, sociability, and eventually sleepiness without loss of mental clarity at moderate doses. Higher doses produce marked sedation and somnolence. The sedative action involves GABA-A potentiation and sodium channel blockade. LaPorte et al. (2011) systematic review found that kava does not significantly impair cognition at typical anxiolytic doses, distinguishing it favorably from pharmaceutical sedatives.
[7, 8, 13]Relieves pain
Local anesthetic and systemic analgesic properties are well recognized in traditional use. Kavain produces numbness of oral mucous membranes (characteristic tingling/numbing of the tongue and lips when drinking kava). Kavalactones demonstrate analgesic effects in animal models, with kavain showing potency comparable to aspirin. Mechanisms include sodium channel blockade (similar to local anesthetics), modulation of pain signaling pathways, and anti-inflammatory effects. Traditional use for headache, muscle pain, and urogenital pain.
[3, 13]Relieves smooth muscle spasm
Kavalactones produce direct smooth muscle relaxation via calcium channel modulation and sodium channel blockade. Skeletal muscle relaxant effects are also well documented, contributing to the physical relaxation characteristic of kava consumption. Traditional use for menstrual cramps, urinary spasm, and muscle tension. The muscle relaxant effect is additive with the anxiolytic effect, making kava particularly useful for anxiety accompanied by physical tension.
[2, 3, 13]Supports and calms the nervous system
Supports and tonifies the nervous system. In traditional Pacific Island medicine, kava is considered a restorative for the nervous system -- calming nervous excitability, reducing worry, and promoting peaceful states of mind. The combination of anxiolytic, sedative, and muscle relaxant effects positions kava as a comprehensive nervine relaxant.
[4, 13]Reduces inflammation
Kavalactones and flavokavains demonstrate anti-inflammatory activity in preclinical models. Kavain and methysticin inhibit COX-2 and suppress TNF-alpha and IL-6 production in vitro. Flavokavains A and B inhibit NF-kB signaling. The anti-inflammatory action is considered secondary to the primary anxiolytic and sedative effects but contributes to the analgesic properties.
[20, 21]Increases urine production and output
Mild diuretic effect has been noted traditionally and in clinical observations. Pacific Islanders report increased urination after kava consumption. The mechanism is not well characterized but may relate to smooth muscle relaxation of the urinary tract and direct effects on renal function. Traditional Polynesian use for urinary tract complaints.
[13]Therapeutic Indications
Nervous System
Generalized anxiety disorder (GAD)
The strongest clinical evidence for kava. Pittler & Ernst (2003) Cochrane systematic review of 11 RCTs (n=645) concluded kava extract is superior to placebo for short-term treatment of anxiety (SMD -1.1, 95% CI -2.0 to -0.2). Sarris et al. (2013) RCT (n=75) demonstrated significant anxiolytic effect in participants with GAD using aqueous kava extract (120-240 mg kavalactones/day) over 6 weeks, with response rates of 26% vs 6% for placebo (P=0.04). Kuchta et al. (2021) observational study of 156 patients confirmed significant improvement in 12 symptoms of nervous anxiety and tension. Commission E originally approved (1990) for nervous anxiety, stress, and restlessness.
[1, 5, 6, 10]Stress and nervous tension
Traditional primary indication across all Pacific Island cultures. Commission E approved indication (prior to withdrawal). The combination of anxiolytic, sedative, and muscle relaxant effects makes kava particularly effective for stress with somatic symptoms (muscle tension, restlessness, irritability). Does not impair cognitive function at standard anxiolytic doses, as confirmed by LaPorte et al. (2011) systematic review.
[1, 7, 8]Insomnia (anxiety-related)
Kava's sedative effects at higher doses support its traditional use for sleep difficulties, particularly when insomnia is driven by anxiety or racing thoughts. Dose-dependent: anxiolytic effects at lower doses (60-120 mg kavalactones), sedative effects at higher doses (150-300 mg kavalactones). Not a first-line standalone sleep aid but effective when insomnia co-occurs with anxiety.
[7, 13]Benzodiazepine withdrawal support
Preliminary clinical data suggest kava may facilitate benzodiazepine tapering. Malsch & Kieser (2001) double-blind RCT in 40 patients showed kava extract (WS 1490, 300 mg/day) was effective in treating anxiety during benzodiazepine taper, with no increase in withdrawal symptoms. This application requires close medical supervision. The distinct mechanism of action (non-benzodiazepine GABA modulation) makes it a theoretically rational adjunct.
[7, 12]Musculoskeletal System
Muscle tension and spasm
Kavalactones produce skeletal muscle relaxation via sodium and calcium channel blockade. Traditional Pacific Island use for muscle pain and tension. The combined muscle relaxant and analgesic effects provide dual benefit for musculoskeletal complaints. Particularly indicated when muscle tension is secondary to anxiety or stress.
[3, 13]Headache (tension-type)
Traditional use in Pacific Island medicine for headache. The combined analgesic, muscle relaxant, and anxiolytic effects are relevant to tension-type headache. Limited clinical data specific to headache as a primary indication.
[13]Urinary System
Urinary tract discomfort and irritation
Traditional Polynesian and Melanesian use for urinary tract complaints. The antispasmodic action on smooth muscle may relieve urinary urgency and spasm. The mild diuretic effect complements this indication. Used traditionally for conditions described as 'difficult urination' and 'urinary pain.'
[13]Reproductive System
Energetics
Temperature
warm
Moisture
slightly dry
Taste
Tissue States
wind/tension, hot/excitation, cold/constriction
In Western herbal energetics, kava is classified as warm and slightly drying, with a distinctly pungent and acrid taste that produces characteristic numbing of the oral mucosa. The warming quality aligns with its ability to relax tension, promote circulation, and ease the 'cold constriction' of anxiety and fear. The pungent/acrid taste reflects its direct action on nerve endings (sodium channel blockade producing the numbing sensation). The bitter undertone indicates its ability to stimulate digestive secretions, though this is not its primary use. Kava is specifically indicated for 'wind/tension' tissue states -- anxiety, muscular tension, nervous restlessness, and spasm. It also addresses 'hot/excitation' states when nervous agitation and insomnia are driven by an overactive sympathetic nervous system. Its warming nature can address 'cold/constriction' patterns where anxiety manifests as physical tightness, withdrawal, and inhibition. In Hawaiian traditional medicine, 'awa is associated with the god Ku and the element of earth, representing grounding and stability. CAVEAT: Herbal energetics are interpretive frameworks within Western herbalism, not standardized across all practitioners.
Traditional Uses
Pacific Island ceremonial and social use (pan-Pacific)
- Ceremonial beverage for welcoming dignitaries, marking important occasions, and religious rituals
- Social lubricant consumed communally to promote relaxation, sociability, and conflict resolution
- Anxiolytic and calming drink consumed in the evening after work
- Mediator of communication with ancestors and the spirit world in traditional religion
- Peacemaking rituals -- shared kava drinking to resolve disputes between individuals or communities
"Kava has been central to Pacific Island cultures for over 3,000 years. The preparation and communal consumption of kava is the most significant social and ceremonial practice across Melanesia and Polynesia. Captain James Cook's expeditions (1768-1779) produced the first detailed Western accounts of kava ceremonies. In Fiji, the 'yaqona' ceremony remains an essential diplomatic and social institution. In Tonga, the 'taumafa kava' royal kava ceremony is a state ritual of the highest order."
Hawaiian traditional medicine ('awa)
- Treatment of general debility and fatigue ('awa as a restorative)
- Relief of headache and body aches
- Urinary tract complaints and difficult urination
- Chills, colds, and respiratory congestion
- Insomnia and restlessness
- Skin diseases (topical application of chewed root)
- Purification and spiritual cleansing rituals
"In Hawaiian tradition, 'awa is one of the most important medicinal and ceremonial plants, associated with the god Ku and the god of medicine, Lono. Traditional healers (kahuna la'au lapa'au) prescribed specific 'awa cultivars for different conditions. The Hawaiian pharmacopoeia recognized approximately 13 named cultivars, each with distinct properties and uses. Showman et al. (2015) documented the intersection of Pacific indigenous knowledge and Western pharmacology regarding 'awa."
Fijian traditional medicine
- Relief of anxiety and nervousness
- Treatment of urogenital conditions including gonorrhea and urinary inflammation
- Headache and migraine relief
- Relief of menstrual discomfort
- General analgesic for toothache and mouth pain (chewed root applied locally)
- Treatment of respiratory illness
"In Fiji, yaqona is deeply integrated into daily life and medicine. Traditional healers use specific preparations of kava root for a wide range of conditions. The aqueous preparation method -- root is chewed, pounded, or ground and steeped in cold water, then strained through hibiscus bark fiber -- has been practiced for millennia and represents the preparation with the longest safety record."
Vanuatu (ni-Vanuatu) traditional medicine
- Anxiety, nervousness, and mental unrest
- General pain relief
- Treatment of gonorrhea and urinary complaints
- Women's health including menstrual disorders
- Sedation for ritual purposes
- Treatment of asthma and respiratory complaints
"Vanuatu is the likely center of origin for cultivated kava and maintains the greatest diversity of cultivars (over 80 named varieties). Ni-Vanuatu traditional knowledge distinguishes sharply between 'noble' cultivars suitable for daily consumption and 'tudei' (two-day) varieties with stronger and longer-lasting effects used only for special purposes. This traditional classification system has been validated by modern phytochemical analysis showing distinct kavalactone chemotypes."
European and Western phytotherapy (19th-21st century)
- Nervous anxiety and restlessness (Commission E approved indication)
- Stress-related insomnia
- Muscle tension and spasm associated with anxiety
- Urinary tract irritability
- Alternative to benzodiazepines for non-pathological anxiety
"Kava was introduced to Western medicine through colonial-era botanical collections and ethnobotanical reports. By the late 19th century, European physicians had begun prescribing kava preparations for nervousness and urogenital complaints. The Commission E positive monograph (1990) marked formal acceptance into the German phytotherapy system, and kava became one of the best-selling herbal products in Europe and the US during the 1990s, until the hepatotoxicity controversy of 2001-2002 led to regulatory restrictions."
Modern Research
Cochrane systematic review: kava extract for anxiety
Cochrane systematic review and meta-analysis of randomized, placebo-controlled trials evaluating kava extract (predominantly WS 1490) for the treatment of anxiety symptoms in outpatient populations.
Findings: Analysis of 11 trials (n=645) found kava extract significantly superior to placebo for reducing anxiety as measured by the Hamilton Anxiety Rating Scale (HAM-A). The pooled standardized mean difference was -1.1 (95% CI: -2.0 to -0.2) in favor of kava. Effects were consistent across most included trials. The magnitude of the anxiolytic effect was considered clinically meaningful. The authors concluded that kava extract appears to be an effective symptomatic treatment for anxiety.
Limitations: Substantial heterogeneity between studies. Most trials used a single proprietary extract (WS 1490). Relatively small individual study sizes. Short treatment durations (typically 4-25 weeks). Publication bias could not be excluded. Updated versions of the review have not been published since 2003.
[5]
Aqueous kava extract RCT for generalized anxiety disorder
Double-blind, randomized, placebo-controlled trial investigating an aqueous kava extract (120-240 mg kavalactones/day, titrated based on response) in 75 participants with current DSM-IV GAD and no comorbid mood disorder, conducted over 6 weeks.
Findings: The kava group showed a significant reduction in HAM-A scores compared to placebo (P=0.046). Response rates (50% or greater reduction in HAM-A) were significantly higher in the kava group (26%) vs placebo (6%, P=0.04). The effect was more pronounced in participants with higher baseline anxiety. Importantly, this trial used an aqueous extract rather than the organic solvent extracts implicated in hepatotoxicity. Liver function tests showed no significant between-group differences, supporting the hepatic safety of aqueous preparations.
Limitations: Modest sample size (n=75). Six-week duration. Response rate, while statistically significant, was modest in absolute terms (26%). Single-center. The aqueous extraction method differs from many commercial products.
[6]
Comprehensive review of kava efficacy, safety, and psychopharmacology
Systematic review of kava's pharmacology, clinical efficacy evidence, safety profile, and drug interactions, synthesizing data from clinical trials, pharmacological studies, and case reports.
Findings: Confirmed anxiolytic efficacy based on multiple RCTs. Identified multiple mechanisms: GABA modulation via lipid membrane interaction, sodium/calcium channel blockade, MAO-B inhibition, noradrenaline and dopamine reuptake inhibition. Concluded that kava does not appear to produce cognitive impairment at standard anxiolytic doses. Reviewed the hepatotoxicity evidence and identified contributing factors including poor-quality raw material, use of non-root plant parts, organic solvent extraction, and possible genetic susceptibility (CYP2D6 poor metabolizers).
Limitations: Narrative synthesis of heterogeneous evidence. Safety conclusions necessarily limited by incomplete reporting of hepatotoxicity cases. Mechanistic data largely from in vitro and animal studies.
[7]
Neurocognitive effects of kava: systematic review
Systematic review of clinical studies assessing the effects of kava on cognitive performance, including attention, memory, reaction time, and psychomotor function.
Findings: Analysis of available clinical trials found that kava at standard anxiolytic doses (60-240 mg kavalactones/day) does not produce significant cognitive impairment. Some studies suggested possible cognitive enhancement, potentially through anxiety reduction improving test performance. At higher doses, mild impairment of visuomotor tracking was observed. Kava demonstrated a favorable cognitive profile compared to benzodiazepines, which consistently impair cognition.
Limitations: Limited number of studies available for review. Heterogeneity in cognitive measures used. Most studies assessed acute rather than chronic dosing effects. Potential for floor/ceiling effects in cognitive testing.
[8]
Kava hepatotoxicity: clinical review and risk analysis
Critical clinical review of all published case reports of suspected kava hepatotoxicity, analyzing the quality of evidence, confounding factors, and plausible mechanisms for liver injury.
Findings: Identified approximately 100 case reports of suspected kava hepatotoxicity reported to regulatory authorities worldwide, with approximately 11 cases of liver failure requiring transplantation. However, critical analysis revealed that many cases had poor documentation, confounding factors (concurrent hepatotoxic medications, pre-existing liver disease, excessive alcohol use), or lacked definitive causality assessment. Key contributing factors identified: use of ethanolic or acetonic extracts (rather than traditional aqueous preparations), possible adulteration with aerial plant parts containing pipermethystine, use of non-noble (tudei) cultivars, genetic susceptibility (CYP2D6 poor metabolizer status), and pre-existing hepatic compromise. The estimated incidence of hepatotoxicity from kava products was calculated at approximately 0.008 per 1 million daily doses -- lower than the rate for many conventional anxiolytics.
Limitations: Retrospective case review with inherent limitations of spontaneous adverse event reporting. Many cases lacked sufficient documentation for definitive causality assessment. Heterogeneous products and preparations across cases. No prospective pharmacovigilance data available.
[11]
Pacific and Western perspectives on kava toxicology
Collaborative study between Pacific indigenous scientists, Hawaiian cultural practitioners, and Western pharmacologists examining kava toxicology from both traditional knowledge and modern scientific perspectives.
Findings: Identified that traditional Pacific Island preparation and consumption practices -- using only root/rhizome of noble cultivars, aqueous (cold water) extraction, and moderate consumption patterns -- have a multi-millennial safety record with no documented epidemic of liver disease in kava-consuming populations. Highlighted that the hepatotoxicity cases were concentrated in Western commercial products using organic solvent extracts, potentially non-noble cultivars, and possibly contaminated with aerial plant parts. Concluded that respecting traditional preparation parameters is key to safe use.
Limitations: Primarily qualitative and narrative in approach. Traditional safety record assessment is epidemiological inference rather than controlled study. Some cultural knowledge is oral tradition without formal documentation.
[15]
Re-introduction of kava to the EU: regulatory and safety considerations
Review examining the evidence for and against reintroducing kava products to European markets, analyzing the hepatotoxicity data, quality control issues, and regulatory framework.
Findings: Concluded that the hepatotoxicity risk was plausibly linked to specific quality and preparation factors rather than an inherent property of properly prepared kava root. Identified five key factors for safe kava products: (1) use of noble cultivar roots only, (2) peeled root/rhizome without aerial parts, (3) aqueous or hydroethanolic extraction rather than acetonic extraction, (4) standardized kavalactone content, and (5) appropriate labeling with contraindications. Proposed quality standards that could enable safe reintroduction to European markets.
Limitations: Advocacy-oriented review. Some conclusions based on plausible inference rather than definitive evidence. Regulatory decisions involve political and legal factors beyond scientific evidence alone.
[23]
Kava as a clinical nutrient: anti-inflammatory and anticancer potential
Review of emerging evidence for kava and kavalactone bioactivity beyond anxiolysis, including anti-inflammatory and anticancer properties.
Findings: Summarized preclinical evidence showing kavalactones and flavokavains possess anti-inflammatory activity through suppression of NF-kB, TNF-alpha, and COX-2 pathways. Flavokavains demonstrated selective cytotoxicity against cancer cell lines (bladder, prostate, lung, colon) with apoptosis induction via multiple pathways. Epidemiological data from Pacific Islands showed lower cancer incidence in populations with regular kava consumption, though confounding factors exist. Cautioned that flavokavain B also shows hepatotoxic potential, requiring careful dose-response characterization.
Limitations: Largely preclinical evidence. Epidemiological associations do not establish causation. Anticancer doses may not be achievable with safe oral consumption. Hepatotoxicity of flavokavains at higher doses is a concern.
[20]
Biological activity, hepatotoxicity, and structure-activity relationship of kavalactones and flavokavains
Comprehensive review of structure-activity relationships for kavalactones and flavokavains, examining how structural features relate to both therapeutic activity and hepatotoxic potential.
Findings: Kavalactones with methylenedioxy groups (methysticin, dihydromethysticin) showed greater CYP inhibitory potency, potentially contributing to drug interactions and metabolic-mediated hepatotoxicity. Flavokavain B was identified as the most hepatotoxic constituent, inducing mitochondrial toxicity and oxidative stress in hepatocytes. Noble cultivars with kavain-dominant chemotypes showed lower hepatotoxic potential than tudei cultivars with higher dihydromethysticin and flavokavain B content. Proposed that kavalactone:flavokavain ratio is a useful quality parameter for safety assessment.
Limitations: Primarily in vitro and in silico structure-activity analyses. Translation to in vivo human hepatotoxicity risk is uncertain. Dose-response relationships for hepatotoxicity not fully characterized in humans.
[21]
Safety review of kava extract in anxiety treatment
Systematic review of clinical evidence relating to the safety of kava extracts used in RCTs for anxiety, examining adverse event profiles from clinical trials and post-marketing surveillance data.
Findings: Short-term clinical trial data showed kava extract was well tolerated with adverse events similar to placebo. Most commonly reported side effects were mild GI symptoms, headache, and dizziness. No hepatotoxic events were observed in any of the controlled clinical trials. Post-marketing surveillance data from over 4,000 patients in observational studies also showed a favorable safety profile. The authors concluded that the safety profile of kava in clinical trials was acceptable.
Limitations: Published before the main wave of hepatotoxicity reports (2001-2002). Clinical trial populations are selected and may not represent the general user population. Short treatment durations may not capture delayed adverse effects.
[9]
Kava extract for nervous anxiety, tension, and restlessness: observational study
Observational study documenting clinical outcomes in 156 patients treated with kava extract for nervous anxiety, tension, and restlessness, assessing 12 symptom domains.
Findings: All 12 assessed symptoms showed significant and clinically relevant improvements. The most effective results were seen for nervous anxiety, inner tension, and restlessness. Median duration of treatment was 28 days. The perceived onset of effects was relatively rapid. Safety was rated as excellent, with no liver-related adverse events reported.
Limitations: Non-controlled observational design. No placebo comparison. Potential for expectation effects. Single product assessed. Documentation primarily from clinical practice records rather than formal trial protocol.
[10]
Preparations & Dosage
Decoction
Strength: Approximately 30-60 g dried root per 500-1000 mL cold water
Traditional Pacific Island method: Pound or grind 30-60 g fresh or dried, peeled kava root. Place in a muslin cloth or traditional strainer (hibiscus bark fiber). Knead and squeeze repeatedly in 500-1000 mL of cold or room-temperature water for 10-20 minutes until the water becomes opaque and muddy brown. Strain thoroughly. Consume promptly. IMPORTANT: Traditional preparation uses COLD water, not boiling. Cold-water extraction preferentially extracts kavalactones while leaving behind some less desirable compounds.
100-250 mL of the strained beverage, containing approximately 150-500 mg total kavalactones per serving depending on root quantity and extraction efficiency
1-3 servings per session, traditionally consumed in the evening. For therapeutic anxiety management, 1-2 servings daily
Traditional use is intermittent and social. For therapeutic use, limit to 3 months without practitioner supervision. Periodic liver function monitoring recommended for continuous use beyond 1 month.
Not recommended for children under 18 years
The traditional cold-water aqueous extraction is the preparation with the longest safety record (3,000+ years of Pacific Island use). This method extracts kavalactones as an emulsion stabilized by root starches and fibers. It does NOT efficiently extract the potentially hepatotoxic alkaloid pipermethystine (even if trace amounts are present in the root). Glutathione and other protective thiols present in fresh root are preserved in aqueous but not in organic solvent extracts. This preparation is preferred over organic solvent extracts from a safety perspective. Note that chronic heavy consumption via traditional preparation can produce kava dermopathy (Norton & Ruze 1994), a reversible ichthyosiform skin eruption.
Tincture
Strength: 1:3 to 1:5, 60-70% ethanol
Hydroethanolic extraction of dried, peeled kava root. Standard ratio 1:3 to 1:5 in 60-70% ethanol. Macerate for 4-6 weeks with regular agitation, then press and filter.
3-6 mL (60-120 drops) 2-3 times daily, equivalent to approximately 50-150 mg kavalactones per day
2-3 times daily, or as a single evening dose for sleep support
Limit to 2-3 months without practitioner supervision. Monitor liver function if used continuously.
Not recommended for children under 18 years
Tincture provides efficient extraction of lipophilic kavalactones. Higher alcohol content is needed compared to many other herbal tinctures due to the lipophilic nature of kavalactones. CAUTION: The use of alcohol as a solvent is notable given the absolute contraindication of combining kava with alcohol consumption. However, the amount of ethanol in a typical tincture dose (3-6 mL) is pharmacologically negligible (less than a teaspoon of 60% alcohol). Patients with liver disease or alcohol use disorder should use non-alcoholic preparations.
Capsule / Powder
Strength: Crude dried root powder, typically 500-1000 mg per capsule. Kavalactone content varies by cultivar (3-20% of dried root weight).
Dried, peeled kava root powder encapsulated. Choose products from noble kava cultivars only, standardized or with certificate of analysis for kavalactone content.
1500-3000 mg dried root powder daily in divided doses (equivalent to approximately 60-200 mg kavalactones depending on root quality)
2-3 times daily with water
Limit to 3 months without practitioner supervision
Not recommended for children under 18 years
Dried root powder capsules provide all root constituents including kavalactones, flavokavains, and matrix compounds. Less potent per weight than standardized extracts but may benefit from whole-root synergy. Quality varies significantly between products -- choose products with verified noble cultivar sourcing and third-party kavalactone testing.
[3]
Standardized Extract
Strength: DER 11-20:1. WS 1490: standardized to 70% kavalactones. Aqueous extracts: standardized to 30-50% kavalactones. Clinical dose: 100-250 mg total kavalactones daily.
Capsules or tablets containing concentrated kava root extract standardized to kavalactone content. The most clinically studied form. WS 1490 is the most-studied extract (ethanol/water extraction, 70% kavalactones). Newer aqueous-based extracts are also available.
60-240 mg kavalactones daily in divided doses. For anxiety: 100-250 mg kavalactones per day. Sarris et al. (2013) used 120-240 mg kavalactones/day. Most European clinical trials used WS 1490 at 210 mg kavalactones/day (3 x 100 mg extract capsules containing 70 mg kavalactones each).
2-3 times daily. For sleep, a single dose 1-2 hours before bedtime
Clinical trials used 4-25 weeks safely. Limit to 3 months without professional supervision. Periodic liver function testing (AST, ALT, GGT, bilirubin) recommended every 4-6 weeks during continuous use.
Not recommended for children under 18 years
Standardized extracts are the form used in most clinical trials demonstrating anxiolytic efficacy. WS 1490 (Laitan/Antares) was used in the majority of the Cochrane-reviewed trials. When selecting a standardized extract, prefer products: (1) derived from noble cultivar root only, (2) with verified kavalactone content and chemotype profile, (3) with absence of pipermethystine verified by testing, (4) from manufacturers providing Certificate of Analysis. AQUEOUS standardized extracts are preferred over acetonic extracts from a safety perspective.
Safety & Interactions
Class 2d
Other specific use restrictions apply (AHPA Botanical Safety Handbook)
Contraindications
Kava is absolutely contraindicated in individuals with any pre-existing liver disease, including hepatitis, cirrhosis, fatty liver disease, or elevated liver enzymes of any etiology. The rare but serious hepatotoxicity associated with kava use (see adverseEffects and detailed notes below) presents an unacceptable risk in individuals with compromised hepatic function. All major regulatory authorities and monograph sources agree on this contraindication.
Alcohol and kava must NOT be combined. This is both a pharmacodynamic interaction (additive CNS depression) and a pharmacokinetic/hepatotoxic concern: both alcohol and kava are metabolized by the liver, and alcohol depletes glutathione, which may be protective against kavalactone-mediated oxidative stress. Several of the reported hepatotoxicity cases involved concurrent alcohol use. Additionally, ethanol potentiates the sedative effects of kavalactones, increasing the risk of excessive CNS depression. The AHPA classification of 2d specifically references the alcohol restriction.
Kava should not be used concurrently with known hepatotoxic drugs, including acetaminophen/paracetamol (at high doses), methotrexate, ketoconazole, isoniazid, statins (at high doses), or other drugs with documented hepatotoxicity. The combined hepatic burden may increase the risk of liver injury. The discovery that aerial plant parts contain the hepatotoxic alkaloid pipermethystine (Dragull et al. 2003) underscores the importance of using only verified root/rhizome preparations.
Kava is contraindicated during pregnancy due to: (1) potential uterotonic effects, (2) unknown effects on fetal development, (3) hepatotoxicity risk in a population already at risk for pregnancy-related liver conditions, and (4) lack of safety data. Traditional Pacific Island cultures also generally restrict kava use during pregnancy.
Kavalactones may pass into breast milk. CNS depressant effects on the nursing infant are a concern. Insufficient safety data. Contraindicated during breastfeeding.
No safety data for pediatric use. CNS depressant effects are inappropriate for developing nervous systems. Not recommended for children or adolescents.
CYP2D6 poor metabolizers may have reduced capacity to metabolize kavalactones, leading to higher systemic exposure and potentially increased risk of adverse effects including hepatotoxicity. Genetic polymorphisms in CYP2D6 are more common in Caucasian populations (5-10%) than in Pacific Islander populations, which may partly explain why hepatotoxicity has been reported primarily in Western users. Where pharmacogenomic testing is available, CYP2D6 poor metabolizers should avoid kava or use only under close medical supervision.
Commission E noted endogenous depression as a contraindication, likely due to the sedative effects potentially worsening depressive symptoms. Kava should not be used as a substitute for appropriate treatment of clinical depression.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| Alcohol (ethanol) (CNS depressants / hepatotoxins) | contraindicated | Additive CNS depression (both kava and alcohol are CNS depressants acting on GABA systems). Additive hepatotoxic potential: both are metabolized by the liver, and alcohol depletes glutathione, which may be protective against kavalactone-induced oxidative stress. Alcohol also induces CYP2E1, which may produce toxic metabolites of kavalactones. |
| Benzodiazepines (alprazolam, diazepam, lorazepam, etc.) (Anxiolytics / sedative-hypnotics) | major | Both kava and benzodiazepines enhance GABAergic neurotransmission, though by different mechanisms (kavalactones modulate GABA-A via lipid membrane effects, benzodiazepines bind the allosteric benzodiazepine site). Additive CNS depression including sedation, impaired psychomotor function, and respiratory depression. One case report of coma-like unconsciousness in a patient combining kava with alprazolam. |
| Levodopa (L-DOPA) (Anti-Parkinson agents) | major | Kavalactones have dopamine antagonist properties and may reduce the efficacy of levodopa. A case report described a woman whose Parkinson's symptoms worsened after initiating kava use while on levodopa therapy. Additionally, rare extrapyramidal reactions with kava suggest dopaminergic interference. |
| CYP2E1 substrates (acetaminophen/paracetamol, enflurane, theophylline, ethanol) (CYP2E1 substrates) | moderate | Kavalactones (particularly methysticin and dihydromethysticin) inhibit CYP2E1, which could alter the metabolism of CYP2E1 substrates. CYP2E1 converts acetaminophen to the hepatotoxic metabolite NAPQI. While CYP2E1 inhibition by kava would theoretically REDUCE NAPQI formation, the combined hepatic stress of kava and high-dose acetaminophen is a concern. |
| CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 substrates (Multiple CYP substrate classes) | moderate | Kavalactones, particularly methysticin and dihydromethysticin, demonstrate broad CYP inhibitory activity in vitro. Clinically relevant inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 has been demonstrated in vitro at concentrations achievable with therapeutic kava doses. This could increase blood levels of many pharmaceutical drugs metabolized by these enzymes. |
| Other CNS depressants (opioids, barbiturates, sedating antihistamines, muscle relaxants) (CNS depressants) | moderate | Additive CNS depression through pharmacodynamic interaction. Kavalactones enhance GABAergic, sodium channel-blocking, and possibly opioidergic neurotransmission, which can potentiate the effects of other CNS depressants. |
| Hepatotoxic drugs (methotrexate, ketoconazole, isoniazid, high-dose statins) (Hepatotoxic medications) | major | Combined hepatotoxic burden. Kava has been associated with rare hepatotoxicity, and concurrent use of other hepatotoxic medications increases the cumulative risk to the liver. Several reported kava hepatotoxicity cases involved concurrent use of other potentially hepatotoxic drugs. |
| Anticonvulsants (phenobarbital, phenytoin, carbamazepine) (Anticonvulsants / antiepileptics) | moderate | Additive CNS depression and potential pharmacokinetic interactions via CYP inhibition. Kavalactones also have independent anticonvulsant properties, which could either complement or complicate anticonvulsant therapy. CYP2C9/2C19 inhibition could affect phenytoin metabolism. |
Pregnancy & Lactation
Pregnancy
unsafe
Lactation
unsafe
Kava is contraindicated during pregnancy and lactation. Kavalactones cross biological membranes readily and are likely to cross the placenta and enter breast milk. Animal studies have shown effects on uterine tone. There is no safety data for kava use during pregnancy or lactation in humans. Traditional Pacific Island cultures generally restrict kava consumption during pregnancy. The WHO Assessment on Kava (2007) explicitly lists pregnancy and lactation as contraindications. The hepatotoxicity risk adds an additional dimension of concern during pregnancy, when the liver is already under increased metabolic stress.
Adverse Effects
References
Monograph Sources
- [1] German Commission E (Bundesinstitut fur Arzneimittel und Medizinprodukte). Commission E Monograph: Piperis methystici rhizoma (Kava-Kava) -- Originally Positive (1990), Withdrawn (2002). Bundesanzeiger (Federal Gazette) (1990)
- [2] World Health Organization. WHO Assessment of the Risk of Hepatotoxicity with Kava Products. World Health Organization, Geneva (2007)
- [3] Blumenthal M, Goldberg A, Brinckmann J (eds). Herbal Medicine: Expanded Commission E Monographs. American Botanical Council, Austin, TX / Integrative Medicine Communications, Newton, MA (2000) . ISBN: 978-0967077215
- [4] Hoffmann D. Medical Herbalism: The Science and Practice of Herbal Medicine. Healing Arts Press, Rochester, VT (2003) . ISBN: 978-0892817498
Clinical Studies
- [5] Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety. Cochrane Database Syst Rev (2003) ; 1 : CD003383 . DOI: 10.1002/14651858.CD003383 . PMID: 12535473
- [6] Sarris J, Stough C, Bousman CA, Wahid ZT, Murray G, Teschke R, Savage KM, Stough C, Byrne GJ, Scholey A. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol (2013) ; 33 : 643-648 . DOI: 10.1097/JCP.0b013e318291be67 . PMID: 23635869
- [7] Sarris J, LaPorte E, Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry (2011) ; 45 : 27-35 . DOI: 10.3109/00048674.2010.522554 . PMID: 21073405
- [8] LaPorte E, Sarris J, Stough C, Scholey A. Neurocognitive effects of kava (Piper methysticum): a systematic review. Hum Psychopharmacol (2011) ; 26 : 102-111 . DOI: 10.1002/hup.1180 . PMID: 21437989
- [9] Stevinson C, Huntley A, Ernst E. A systematic review of the safety of kava extract in the treatment of anxiety. Drug Saf (2002) ; 25 : 251-261 . PMID: 11994028
- [10] Kuchta K, Hladikova M, Thomsen M, Gajduschek H, Schmidt M. Kava (Piper methysticum) Extract for the Treatment of Nervous Anxiety, Tension and Restlessness. Drug Res (Stuttg) (2021) ; 71 : 83-89 . DOI: 10.1055/a-1268-7135 . PMID: 33207379
- [11] Teschke R. Kava hepatotoxicity--a clinical review. Ann Hepatol (2010) ; 9 : 251-265 . PMID: 20720265
- [12] Sarris J. Herbal medicines in the treatment of psychiatric disorders: 10-year updated review. Phytother Res (2018) ; 32 : 1147-1162 . DOI: 10.1002/ptr.6055 . PMID: 29575228
Traditional Texts
- [13] Singh YN. Kava: an overview. J Ethnopharmacol (1992) ; 37 : 13-45 . PMID: 1453702
- [14] Lebot V, Merlin M, Lindstrom L. Kava: The Pacific Drug. Yale University Press, New Haven, CT (1992) . ISBN: 978-0300052138
- [15] Showman AF, Baker JD, Linares C, Naeole CK, Borber R, Martinez JE, Walmsley NL, Fierro NA. Contemporary Pacific and Western perspectives on 'awa (Piper methysticum) toxicology. Fitoterapia (2015) ; 100 : 56-67 . DOI: 10.1016/j.fitote.2014.11.012 . PMID: 25464054
- [16] Norton SA, Ruze P. Kava dermopathy. J Am Acad Dermatol (1994) ; 31 : 89-97 . PMID: 8021378
Pharmacopeias & Reviews
- [17] Anke J, Ramzan I. Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.). J Ethnopharmacol (2004) ; 93 : 153-160 . PMID: 15234747
- [18] Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs (2009) ; 69 : 1777-1798 . DOI: 10.2165/11317010-000000000-00000 . PMID: 19719333
- [19] Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, Zhou S. Herb-drug interactions: a literature review. Drugs (2005) ; 65 : 1239-1282 . PMID: 15916450
- [20] Bian T, Corral P, Wang Y, Botber J, Xing C. Kava as a Clinical Nutrient: Promises and Challenges. Nutrients (2020) ; 12 : 3044 . DOI: 10.3390/nu12103044 . PMID: 33027883
- [21] Wang Y, Su C, Zhang B, Li J. Biological Activity, Hepatotoxicity, and Structure-Activity Relationship of Kavalactones and Flavokavins, the Two Main Bioactive Components in Kava. Evid Based Complement Alternat Med (2021) ; 2021 : 6851798 . DOI: 10.1155/2021/6851798 . PMID: 34471418
- [22] Dragull K, Yoshida WY, Tang CS. Piperidine alkaloids from Piper methysticum. Phytochemistry (2003) ; 63 : 193-198 . PMID: 12711141
- [23] Sarris J, Teschke R, Stough C, Scholey A, Schweitzer I. Re-introduction of kava (Piper methysticum) to the EU: is there a way forward?. Planta Med (2011) ; 77 : 107-110 . DOI: 10.1055/s-0030-1250290 . PMID: 20814850
Last updated: 2026-03-01 | Status: published
Unlock the Full Materia Medica
This monograph is part of our complete evidence-based herbal reference. Enter your email to get free, unlimited access to all of our monographs.
No spam, ever. Unsubscribe anytime.
You're In!
You now have full access to all of our herbal monographs.